Abstract
Background High-dose long-term use of anabolic-androgenic steroids (AAS) may bring a range of health consequences, including brain and cognitive abnormalities. We performed age prediction based on brain scans to test whether prolonged AAS use is associated with accentuated brain aging.
Methods T1-weighted MRI (3D MPRAGE) scans were obtained from male weightlifters with a history of prolonged (n=130) or no (n=99) AAS use. We trained machine learning models on combinations of regional brain volumes, cortical thickness and surface area in an independent training set of 1838 healthy males (18-92 years) and predicted brain age for each participant in our study. Including cross-sectional and longitudinal (mean interval 3.5 years, n=76) MRI data, we used linear mixed effects (LME) models to compare the gap between chronological age and predicted brain age (the brain age gap, BAG) between the two groups, and tested for group differences in the change rate of BAG. We tested for associations between apparent brain aging and AAS use duration, administration pattern and dependence.
Results AAS users had higher BAG compared to weightlifting controls, associated with dependency and longer history of use. Group differences in BAG could not be explained by other substance use, general cognitive abilities or depression. Longitudinal data revealed no evidence of accelerated brain aging in the overall AAS group, though accelerated brain aging was seen with longer AAS exposure.
Conclusions The findings suggest that long-term high dose AAS use may have adverse effects on brain aging, potentially linked to dependency and exaggerated use of AAS.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
The study is not a clinical trial or intervention study
Funding Statement
This research was funded by grants 2013087, 2016049, 2017025 and 2018075 (Dr Bjornebekk) from the South-Eastern Norway Regional Health Authority, and internal research grants from the Division on Mental Health and Addiction (Dr Bjornebekk). L.T.W. is funded by the European Research Council under the European Unions Horizon 2020 research and innovation program (ERC Starting Grant 802998), the Research Council of Norway (249795, 273345, 298646), the South-East Norway Regional Health Authority (2019101), and the Department of Psychology, University of Oslo. T.K. is funded by the Research Council of Norway (276082).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Regional Committees for Medical and Health Research Ethics South East Norway (REC) (2013/601)
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data sets for model training were partly gathered from public Resources (Links to websites are listed in Table S1). We do not have the ethical permission to share data on our test sample (AAS users and weightlifting controls).